Merck Is At Support And Should Go Higher (Technical Analysis)
Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level that is likely to hold. Keytruda remains a key revenue driver, with potential for continued growth and extended patent protection through a …